fda and compounding tirzepatide Tirzepatide, FDA, Compounding: Understanding the Current Landscape The FDA is proposing a

Curr Sleep Med Rep

Some individuals with genetic markers for heightened GLP-1 sensitivity may tolerate lower starting doses or microdose protocols better, while others may require standard titration schedules

Disclosures Tine A

Mention when palpitations occur, their duration, intensity, and any other associated symptoms

improves with slower dose escalation Vomiting, diarrhea, or constipation Bloating, heartburn, or stomach discomfort Reduced appetite and early fullness Fatigue or headache Less common side effects Injection-site reactions Fatigue or changes in taste Temporary mild hair thinning (limited evidence) Serious but rare risks Pancreatitis seek care immediately if you experience severe abdominal pain Gallbladder disease or gallstones Kidney complications, particularly from dehydration Thyroid C-cell tumor risk in patients with medullary thyroid cancer history or MEN2 Low blood sugar when combined with insulin or sulfonylureas Contact your provider immediately if you experience severe or persistent abdominal pain, constant vomiting, signs of dehydration, yellowing of the skin or eyes, or symptoms of low blood sugar